Kymera Therapeutics
KYMR
256 hedge funds and large institutions have $8.01B invested in Kymera Therapeutics in 2026 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 95 increasing their positions, 73 reducing their positions, and 38 closing their positions.
181.93% more ownership
Funds ownership: 124.88% → 306.81% (+182%)
30% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 73
16% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 38
15% more capital invested
Capital invested by funds: $6.99B → $8.01B (+$1.02B)
8% more funds holding in top 10
Funds holding in top 10: 13 → 14 (+1)
8% more call options, than puts
Call options by funds: $10.8M | Put options by funds: $9.95M
1% more funds holding
Funds holding: 254 → 256 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$383M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$219M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$22.7M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$21.9M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$18.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$41.4M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$18M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13.5M |
| 4 |
Squarepoint
New York
|
-$11.6M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$10.1M |
KYMR Hedge Fund Activity: Q1 2026 in Review
256 of the 8,184 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q1 2026, worth a combined $8.01B — up 15% from $6.99B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new KYMR positions and 38 closed out — a net gain of 6 holders — while 95 added to existing stakes and 73 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $383M. The largest seller was Wellington Management Group, cutting an estimated $41.4M.
- 256 institutional investors held Kymera Therapeutics (KYMR) as of Q1 2026, up from 254 in Q4 2025.
- Funds reported $8.01B of Kymera Therapeutics stock for Q1 2026, up 15% quarter-over-quarter.
- 44 funds opened new Kymera Therapeutics positions in Q1 2026 and 38 closed out, a net change of +6 holders.
- The largest Kymera Therapeutics buyer in Q1 2026 was T. Rowe Price Investment Management, an estimated $383M added.
- The largest Kymera Therapeutics seller in Q1 2026 was Wellington Management Group, an estimated $41.4M sold.
Based on aggregated 13F filings for Q1 2026.